card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

 card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

 card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

 card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

 card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services
WE'RE HIRING

Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

Search jobs website-featured_jpg-2213_cheerful-young-colleagues-using-laptop
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download card-3242_Scientist using tablet while colleagues working behind
3233_discovery

Discovery Sciences

Our labs bring expertise in protein production, antibody discovery, and immunogenicity to help you select the most promising candidates and reduce risk as you move toward IND-enabling studies.
3235_biomarkers

Biomarker analysis

a CLIA-certified biomarker testing laboratory developing immunoassays used to quantify protein biomarkers in support of drug mechanism of action, pharmacodynamic, prognostic, and predictive clinical studies across all stages of drug discovery and development.
2768_CentralLaboratory

Central laboratories

Meeting the demands of today’s drug, device and diagnostics development environment requires a next generation service provider.
3253_bioa

Bioanalytical services

One of the world's largest and most respected bioanalytical and ADME laboratory networks. From our global locations, we serve many of the largest pharmaceutical, specialty pharmaceutical and biotechnology companies worldwide.
182_genomics-1

Genomics

We offer a range of genomic laboratory services to support drug discovery, precision medicine and clinical development. Our industry-leading team advances research by delivering scientific insights that help clients maximize the value of their data.
3214_vaccines

Vaccines

Combining cutting-edge technology platforms and state-of-the-art laboratories with over 35 years of clinical vaccine development.
card-3242_Scientist using tablet while colleagues working behind

Digital innovation

We have a dedicated Digital Innovation department focused on driving operational improvements and quality of our services. We’ve helped create agile and impactful solutions across the organization with the underpinnings of traceability, productivity, quality, and efficiency.
2768_therapeutic_expertise

Therapeutic expertise
Contact Us
English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search
3233_Laboratory scientist working at lab with micropipette, and 96 well plate

Vaccines

Immunotherapy

Advanced Assays To Accelerate Immunotherapy Development

For Cancer Vaccines, Checkpoint Inhibitors, Other Immuno-Oncology Drugs, and More 

An immunotherapy program has the potential to change lives through more effective treatments — with better quality of life — than ever before. At IQVIA Laboratories Vaccines, we provide extensive scientific expertise with a wide range of assay development services with advanced instrumentation to support your efforts, from exploration onward. Partner with us to increase efficiency and accelerate your novel therapies to patients who need them.

Immunotherapy Is a Crucial, Wide-Open Field

The immunotherapy field has rapidly evolved as a promising avenue for cancer treatment, with drugs and therapeutic vaccines that amplify the immune response to disease or help the body identify and target cancer cells. Immunotherapies have been developed to treat many neoplasms, including breast cancer, multiple myeloma, and neuroblastoma.

 

Beyond oncology, recent work on immunotherapies for infectious diseases includes treatments for human immunodeficiency virus (HIV), tuberculosis (TB), human papillomavirus (HPV), and SARS-CoV-2.

Types of Immunotherapy

Immunomodulators follow a variety of strategies to affect the body’s immunologic response to disease.

 

Categories include:
Monoclonal and Bispecific Antibodies

Naked monoclonal antibodies (mAb) are the most common type of immunotherapy used in cancer treatment. These lab-made proteins attack specific parts of a cancer cell or block antigens that stimulate cancer proliferation. Bispecific antibodies present multiple epitopes on one molecule, facilitating novel functionalities. Verified high purity, specificity, and neutralizing activity are crucial to ensure success with all these agents.

 

One example of this type of therapy is immune checkpoint inhibitors. Immune checkpoints are a normal regulatory mechanism to down-regulate the body’s response to an immunologic stimulus. Some cancers stimulate checkpoint targets, weakening the normal immune response. Checkpoint inhibitors prevent proteins from binding with the checkpoint targets, thus maintaining a strong immune response. The next generation of checkpoint inhibitors combine two targets for greater efficacy. For example, a checkpoint target may be combined with a T-cell target, crosslinking T-cells to tumor cells for increased T-cell tumor infiltration and activation.
Adoptive Cell Therapies

T-cells can be modified to be more effective at targeting disease, cultured, and reintroduced to the patient. For example, in CAR-T cell therapy, T-cells with chimeric antigen receptors (CAR) that target the cancer are created. Tumor-infiltrating lymphocyte (TIL) therapy is another example of an adoptive cell therapy.
Oncolytic Virus Therapy

Common viruses are modified to infect and kill cancer cells, reproducing in the process, for an amplified effect. These viruses may also elicit an anti-tumor immune response on the part of the host. An HSV-based oncolytic virus has been approved as a treatment for melanoma.
Prophylactic Cancer Vaccines

Some vaccines prevent the development of a disease by eliciting an immune response against infectious diseases that cause cancer. For instance, the human papillomavirus (HPV) vaccine protects against several types of cancer. Similarly, the hepatitis B vaccine helps prevent liver cancer.

Therapeutic Vaccine Expertise

In contrast to prophylactic vaccines, therapeutic vaccines are given after the patient has contracted the disease. These vaccines stimulate the patient’s immune system to mount a stronger, more specific defense against a particular disease. Therapeutic vaccines may also be used to treat infectious diseases, such as HIV, cholera, and SARS-CoV-2. Our dedication helps clients develop the next class of promising immunotherapeutic agents.

Early Development Explorations in Immunogenicity

Monoclonal antibody (mAb) development is challenging, and bispecific antibodies are exponentially more so. Success depends on immunology-focused, early-stage candidate characterization. Assessing immunogenicity with our in vitro T-cell activation and proliferation assays using human immune cells and our epitope prediction services. With more than 20 years of experience in immunogenicity, IQVIA Laboratories In Vitro Immunology can help you reduce risk and ensure the candidate you advance is efficacious and developable with low immunogenicity for the best outcomes. 

In Vivo Models to Fit Your Needs

Whatever you need, whether it’s infectious disease, or tumor models in species ranging from mice to NHPs, we created models that we tailor to our clients’ needs or our skilled team will develop them with you.

Tailored Protein Sciences

At IQVIA Laboratories Vaccines, high-throughput technology enables rapid recombinant protein expression and purification to produce a large number of antibodies in parallel, allowing for the best candidate selection. We are experts in purification of a wide range of complex proteins produced by a variety of expression platforms. From sequence to well-planned and executed scale-up, our multitalented, flexible scientific team will work with you to ensure quality and consistency in material delivered to suit your needs.

Bioanalysis: ADA Detection and High-Resolution Mass Spectrometry (HRMS)

We offer state-of-the-art, robust, bioanalytical testing to support your immunotherapy programs in a variety of matrices. To complement our protein science services, we offer HRMS assays for antibodies and antibody drug conjugates (ADCs). In addition to conventional LC-MS/MS methods, our, HRMS offers faster method development time and greater sensitivity.

 

In other applications of our bioanalytical platform, we provide assays to evaluate cytokine release syndrome following monoclonal antibody or CAR T-cell therapy. 

Biomarkers: Cytokines, Growth Factors, and More

IQVIA Laboratories Vaccines offers numerous biomarkers related to cell-mediated immunity and the tumor environment. These can all be customized and validated as needed to support your studies. Biomarker assays we offer include BAFF (B-cell activating factor), BCMA (B-cell maturation antigen), CA-125, interferons, interleukins, M-CSF-1 (macrophage colony stimulating factor), MCP-1 (monocyte chemotactic protein-1), TGF β-1 (transforming growth factor β-1, multiple formats), and VCAM-1 (vascular adhesion molecule-1). 

Cellular Assays for Exploring Immunomodulatory Functionality

Early evaluation of the therapeutic potential of your immunomodulatory drug candidate is crucial for efficient development. We’ll help you gain better insights through analysis of immune cell subpopulations such as CD4+/CD8+. Readouts include multiplex flow cytometry, Luminex, ELISpot/Fluorospot, Incucyte®, and more. Our experts provide customized assays using high-quality human immune cells for in vitro screening of monoclonal and bispecific antibodies, proteins, peptides, RNA/DNA vaccines, viruses, etc.